Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 9/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 3/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3245792 | 0.88 | SMN1; SMN2 (0.46) | SMN1; SMN2POLBATMHTTALDH1A1 | |
| SCHEMBL3237722 | 0.86 | GAA (0.50) | SMN1; SMN2GPR88 | |
| SCHEMBL1239640 | 0.78 | POLB (0.50) | MEN1KMT2ASMN1; SMN2POLBATM | |
| SCHEMBL3246970 | 0.78 | MEN1 (0.45) | MEN1KMT2ASMN1; SMN2POLBATM | |
| SCHEMBL13077134 | 0.76 | SMN1; SMN2 (0.50) | KMT2ASMN1; SMN2ATMHTTALDH1A1 | |
| SCHEMBL14438289 | 0.75 | MEN1 (0.50) | MEN1KMT2ASMN1; SMN2POLBHTT | |
| SCHEMBL18539281 | 0.75 | POLB (0.50) | MEN1KMT2ASMN1; SMN2POLBATM | |
| SCHEMBL18539278 | 0.75 | POLB (0.50) | MEN1KMT2ASMN1; SMN2POLBATM | |
| SCHEMBL6813612 | 0.75 | CYP2D6 (0.50) | MEN1KMT2AATMALDH1A1 | |
| SCHEMBL10316558 | 0.74 | SIGMAR1 (0.50) | MEN1KMT2ASMN1; SMN2ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144733-A1 | Compounds, compositions and methods comprising heteroaromatic derivatives | CFTR, PKD1, PKD2 | MEN1 2895/4885KMT2A 4715/4885SMN1; SMN2 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.